Royalty Pharma
Royalty Pharma plc is an American biopharmaceutical buyer and funder of intellectual property royalties based in the life sciences industry. The company operates by acquiring revenue-producing royalties on approved biopharmaceutical products and funding late-stage clinical research trials. Its portfolio of royalty assets includes rights to commercial blockbuster therapies such as Trikafta, Imbruvica, Tysabri, Tremfya, and Spinraza. Principal revenue drivers consist of recurring royalty cash flows generated from the global commercial sales of underlying pharmaceutical products marketed by major drug companies. Royalty Pharma serves global healthcare end markets by providing capital to academic institutions, biotechnology startups, and research hospitals. The enterprise holds a dominant market position as the largest buyer of biopharmaceutical royalties and a premier provider of non-dilutive capital to the life sciences sector. Headquartered in New York City, New York, the company's Class A common stock is listed on the Nasdaq Stock Market under the ticker symbol RPRX.
86 of the funds FundTelligence covers report a position in Royalty Pharma.
- Legal name
- Royalty Pharma Plc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 86
Funds holding Royalty Pharma
- Morgan Stanley US Advantage Fund — Morgan Stanley · 9.64 % (largest positions only, September 2026)
- Morgan Stanley Global Insight — Morgan Stanley · 9.58 % (largest positions only, September 2026)
- Morgan Stanley US Growth Fund — Morgan Stanley · 8.61 % (largest positions only, September 2026)
- C WorldWide Stabile Aksjer — C WorldWide · 5.4 % (largest positions only, October 2026)
- Fondsfinans Global Helse — Fondsfinans · 4.06 % (full portfolio disclosed, October 2026)
- C WorldWide Healthcare Select — C WorldWide · 3.8 % (largest positions only, October 2026)
- Swedbank Robur Healthcare — Swedbank · 2.97 % (full portfolio disclosed, October 2026)
- Cicero Offensiv Hållbar — Cicero Fonder · 2.78 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 86 funds holding it.